Peregrine Pharmaceuticals, Inc.
Period Ending Apr 30, 2014 Apr 30, 2013 Apr 30, 2012 Apr 30, 2011
Total Revenue 22,401 21,683 15,233 13,492
Cost of Revenue 13,110 12,595 10,153 7,296
Gross Profit 9,291 9,088 5,080 6,196
Operating Expenses
Research and Development 27,723 24,306 35,688 29,462
Sales, General and Admin. 17,274 13,134 11,462 11,421
Non-Recurring Items - - - -
Other - - - -
Operating Income (35,706) (28,352) (42,070) (34,687)
Income From Continuing Operations
Add'l Income/Expense Items 349 (1,374) 41 1,052
Earnings Before Interest and Tax (35,357) (28,030) (42,029) (33,635)
Interest Expense 5 54 90 516
Earnings Before Tax (35,362) (28,084) (42,119) (34,151)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (35,362) (29,780) (42,119) (34,151)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (35,362) (29,780) (42,119) (34,151)
Preferred Stock and Other Adjustments (401) - - -
Net Income Applicable to Common Shareholders (35,763) (29,780) (42,119) (34,151)